NCT02652468 - TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2016

Primary Completion Date

September 1, 2018

Study Completion Date

September 17, 2021

Conditions

Lymphoma

Interventions

DRUG

Fludarabine Phosphate

Fludarabine will be administered by IV over approximately 30 minutes for 4 days.

DRUG

Mesna

Given IV over 24 hours starting prior to cyclophosphamide

DRUG

Cyclophosphamide

Given IV for 2 days

RADIATION

Total nodal irradiation

Undergo total lymphoid irradiation

BIOLOGICAL

T Cell-Depleted Hematopoietic Stem Cell Transplantation

Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant

DRUG

Mycophenolate Mofetil

Given PO

DRUG

Tacrolimus

Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient

BIOLOGICAL

Rituximab

Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient

Trial Locations (1)

53705

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors

lead

University of Wisconsin, Madison

OTHER